To read the full story, subscribe or sign in.

CuraGen, Bayer Advance Four Compounds Through Screening

Feb. 1, 2002

One year after signing a $1.4 billion agreement aimed at developing 12 drugs in obesity and diabetes, CuraGen Corp. and partner Bayer Corp. said they have successfully completed screening against four targets. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...